Dupilumab as Effective Therapy for Corticosteroid- Dependent/Resistant Type 2 Inflammation-Related Cutaneous Adverse Reactions.

Shen, C; Wu, N; Yang, L; Wang, B; Liu, T; Tao, J

Shen, C; Wu, N; Yang, L; Wang, B; Liu, T; Tao, J.

Afiliação

Shen C; Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wu N; Hubei Engineering Research Center of Skin Disease Theranostics and Health, Wuhan, China.
Yang L; Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wang B; Hubei Engineering Research Center of Skin Disease Theranostics and Health, Wuhan, China.
Liu T; Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Tao J; Hubei Engineering Research Center of Skin Disease Theranostics and Health, Wuhan, China.

J Investig Allergol Clin Immunol ; 34(2): 145-147, 2024 04.

Article em En | MEDLINE | ID: mdl-38639452

Assuntos

Anticorpos Monoclonais Humanizados; Pele; Humanos; Anticorpos Monoclonais Humanizados/efeitos adversos; Corticosteroides/uso terapêutico; Inflamação

Palavras-chave

Corticosteroid-resistant; DRESS syndrome; Drug rash; Dupilumab; TH2 pathway

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pele / Anticorpos Monoclonais Humanizados Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google